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Ganglion  Impar  Block  With  Botulinum  Toxin  Type  A 
for  Chronic  Perineal  Pain
-A Case Report-
Department of Anesthesiology and Pain Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
Su  J i n L i m,  MD,  Hu e J u ng  Pa r k,  MD,  S a ng  Hoo n  L ee ,  MD,  a nd  Don g  Eon  Moon,  MD
Chronic perineal pain is an often encountered problem, which produces a great degree of functional 
impairment and frustration to the patient and a challenge to the treating physician. The reason for this problem 
is that the region contains diverse anatomic structures with mixed somatic, visceral and autonomic innervations 
affecting bladder and bowel control and sexual function. A blockade of nociceptive and sympathetic supply to 
the perineal region, supplied through the ganglion impar has been shown to benefit patients with chronic 
perineal pain. Several options to this block have been described that chemical neurolysis, radiofrequency 
a b l a t i o n  e t c .  A l t h o u g h  t h e  a n a l g e s i c  e f f e c t  o f  B o t u l i n u m  t o x i n  t y p e  A  ( B o N T - A )  h a s  l o n g  b e e n  c o n s i d e r e d  
secondary to its action for muscle relaxation, BoNT-A also affects the release of the neurotransmitters that 
are involved in pain perception. We describe a patient who was successfully given ganglion impar block with 
BoNT-A.  (Korean  J  Pain  2010;  23:  65-69)
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　　Chronic perineal pain is difficult to treat because the 
perineum consists of various anatomic structures, sym-
p a t h e t i c  n e r v e s ,  a n d  s o m a t i c  n e r v e  f i b e r s  [ 1 ] .  F o r  t h e  
treatment of perineal pain, blockage of the ganglion impar, 
which is located in the most inferior aspect to the sym-
pathetic nervous system, has been introduced. Since then, 
blockage of the ganglion impar has been used to treat dis-
eases, such as perineal or perianal malignant pain, ex-
cessive perianal sweating, rectal tenesmoid pain, and coc-
cygodynia [1-3]. To achieve blockage of the ganglion im-
par, the following methods exist: local anesthetics, con-
comitant use of local anesthetics and steroids, neurolysis 
by the use of alcohol or phenol, and radiofrequency abla-
tion [4]. We performed blockage of the ganglion impar us-
ing Botulinum toxin type A (BoNT-A). The mechanism of 
action of BoNT-A involves blockage of acetylcholine secre-
tion by binding to the presynaptic nerve ending. BoNT-A 
has therefore been used to treat diseases associated with 
excessive muscle contraction [5]. In recent years, attempts 
have been made to use BoNT-A for the treatment of dis-66 Korean J Pain Vol. 23, No. 1, 2010
eases, such as various types of headaches, lower lumbar 
pain, myofascial pain syndrome, and complex regional pain 
syndrome (CRPS), suggesting that the analgesic effect of 
BoNT-A has other mechanisms than the secondary effect 
due to muscle relaxation [6-8]. In a patient with perineal 
pain who did not have a satisfactory treatment outcome 
despite the use of drug therapy and other various types 
of nerve block, we achieved successful reduction of pain 
following blockage of the ganglion impar with the use of 
BoNT-A. Herein we report our case with a review of the 
literature.
CASE  REPORT
　　A 40-year-old man sought evaluation of a 4-year- 
history of perianal and perineal pain, including the testes 
and penis. In this patient, there was no notable history of 
trauma or disease. On MRI and CT scans, which included 
the abdomen and pelvis, there were normal findings. At the 
time of admission, the patient had a visual analog scale 
(VAS) of 8/10. The patient had the persistent presence of 
pain, which was characterized as bursting and explosive. 
Due to the presence of pain, the patient could not assume 
a sitting position for more than 5 minutes. The patient also 
stated that he could not perform work or household chores. 
Four years before the initial onset of pain, the patient had 
been working as aresearch staff in the US. At the time, 
the patient sought evaluation in a urology department un-
der the assumption that the condition originated from the 
prostate gland. Following evaluation, the patient was con-
sidered normal without a discernible etiology for the pain. 
The  patient  was  therefore  transferred  to  a  pain  clinic, 
where the patient was given oral medications (gabapetin 
1,800 mg/da y and m etha d one) in an o u tpatien t setting. 
The patient also received superior hypogastric, caudal, and 
T12-L1 epidural blocks. However, these procedures had no 
effect in reducing the pain. In early February 2007, the 
patient sought evaluation in an outpatient clinic in the US 
due to aggravation of the pain in a lying position, and un-
derwent  blockage  of  the  ganglion  impar;  the  VAS  de-
creased from 8/10 to 4/10. Because the effect was sus-
tained for approximately 1 day, the patient could not am-
bulate for 2 months. During this period, the patient re-
mained in a lying position. Thereafter, the patient under-
w en t b lockage of the gangli on im par on tw o occasions. 
Following this, the pain decreased to a VAS of 4/10. When 
the pain was severe, however, it was a VAS of 8/10. Every 
3 months, the patient underwent blockage of the ganglion 
im par 4 times with the use of ster oids 40 mg each, 4 
times. In September 2008, the patient returned to Korea. 
At the time of his initial outpatient visit, the patient was 
recommended to undergo the blockage of the ganglion im-
par by radiofrequency ablation. A diagnostic blockage was 
first performed using 0.5% bupivacaine 2 ml because the 
patient was concerned about the destruction of the nerve 
ganglion.  The  patient  was  monitored  clinically,  and  3 
m o n t h s  l a t e r ,  t h e  V A S  o f  8 / 1 0  h a d  d e c r e a s e d  t o  5 / 1 0 .  
A p pr o xim a te l y 1 w ee k l a ter, h o w e v er, th e pain r ec urr ed 
with a V AS of 7-8/10. The severity of pain was not sig-
nifican tly diff er en t fr om the pain w hich existed prior to 
treatmen t. The patien t w as theref ore motiv ated to ha v e 
blockage of the ganglion impar using BoNT-A. For block-
age of the ganglion im par, the patient was placed in a 
prone position. A subcutaneous infiltration was performed 
in the superior area of the anococcygeal ligament. This 
area was chosen as a puncture point. Using a C-shaped 
image intensifier, a 22 G, 10 cm block needle in which the 
terminal part was bent at an angle of 30 degrees was ad-
vanced to a distance of 6 cm. Thus, attempts were made 
a t  t h e  s a c r o c o c c y g e a l  j u n c t i o n  t o  r e a c h  t h e  a n t e r i o r  
surface. Following infusion of 2 ml of contrast media, the 
lateral and anterior-posterior views were evaluated (Fig. 
1, 2). Based on the spread pattern of the contrast media, 
the  infusion  was  performed  with  a  concomitant  use  of 
0 .5 %  b u p i v a c a i n e 1 m l  a n d  B o N T - A  80  U . T h e V A S  o f 
7-8/10 decreased to 3/10, but the VAS increased to 5/10 
two months following the blockage. Accordingly, with the 
use of BoNT-A, 2 months following the blockage, the gan-
glion impar was blocked using 0.5% bupivacaine 2 ml and 
BoNT-A 100 U. When the patient underwent blockage us-
ing BoNT-A again, the VAS decreased to 2/10 and this was 
maintained for 6 months. The patient perceived the pres-
ence of perineal pain (a VAS of 5/10) during the sexual in-
tercourse, which led to the third session of blockage of the 
ganglion im par at the same d ose, w hich diminished the 
VAS to 2/10. At present, 3 months following the last treat-
ment, other than perineal pain (a VAS of 4/10), the patient 
has had no problems in performing activities of daily living 
and work, including sitting and walking. The patient has 
maintained a VAS of 2/10. To evaluate the degree of dis-
ability due to chronic pain during activities of daily living, 
a pain disability index (PDI) [9] was administered. The PDI SJ Lim, et al / Ganglion Impar Block With Botulinum Toxin Type A 67
Fig. 2. AP view of the ganglion impar after contrast 
injection.
Fig. 1. Lateral view of the ganglion impar after contrast 
injection.
has seven categories, such as activities associated with 
family/home  responsibilities,  recreation,  social  activities, 
occupation, sexual behaviors, self-care, and life-support 
activities, and scores are given with a scale ranging from 
0 (no disability) to 10 (total disability). According to the 
PDI, scores were 10, 9, 10, 10, 10, 7, and 1, respectively, 
prior to treatment. Following the third session of blockage 
of the ganglion impar using BoNT-A, the PDI scores were 
greatly improved to 2, 2, 2, 2, 4, 3, and 0, respectively. 
These  results  indicate  that  the  patient's  condition  had 
clearly im pro v ed. Curren tly, the patien t has had a sat-
isfactory outcome and is receiving follow-up observation.
DISCUSSION
　　The etiology for CPP may include benign causes, such 
as chronic prostatitis and chronic proctitis, as well as ma-
lignant causes, such as carcinoma of the pelvic organs. 
Infrequently, the cause of pain may be idiopathic. Chronic 
perineal pain is difficult to treat. The ganglion impar is a 
solitary retroperitoneal structure at the level of the sacro-
coccygeal  junction  and  it  marks  the  termination  of  the 
paravertebral sympathetic chain [1,4]. The ganglion impar 
receives the nerve fibers from the sympathetic and para-
sympathetic  nervous  system,  which  are  present  in  the 
lumbar and sacral regions, and it is responsible f or the 
distribution  of  sympathetic  nerve  fibers  in  the  organs 
around the pelvis or reproductive organs [1,4]. The sym-
pathetic nervous system is associated with myriads of pain 
syndromes. A blockage of the sympathetic nerve fibers has 
therefore been used to alleviate pain [1]. A ganglion impar 
block can be used to treat acute or chronic perineal pain 
[1,4]. In addition, blockage of the ganglion impar has been 
used extensively to treat anal or perianal sweating, rectal 
tenesmoid pain, and coccygodynia [1-3]. There exist vari-
ous methods to block the ganglion impar, such as local 
anesthetics, concomitant use of local anesthetics and ste-
roids, alcohol or phenol, and neurolysis by radiofrequency 
ablation [4].
　　W e performed blockage of the ganglion impar using 
BoNT-A. Botulinum toxin is a potent neurotoxin which is 
e x t r a c t e d  f r o m  t h e  e x o t o x i n  o f  Clostridium  botulinum, 
which proliferates in contaminated foods and triggers the 
occurrence of food poisoning. Immunologically, there are 
seven types of antigens. Of these, types A and B have 
been used to treat human diseases [6]. BoNT-A binds to 
the presynaptic nerve endings and blocks the secretion of 
acetylcholine, thus causing a flaccid muscle paralysis. This 
chemodenervation transiently occurs, and while minimizing 
the systemic side effects, it persistently reduces or abol-
ishes the activities of muscles, sweat glands, or muscles 
of contraction for several months [6]. Accordingly, the use 
of BoNT-A is effective in treating diseases associated with 
an excessive contraction of the muscles, including stra-
bismus,  blepharospasm,  unilateral  blepharospasm,  and 
abnormal muscle tension in the neck [5]. Attempts have 68 Korean J Pain Vol. 23, No. 1, 2010
also been made to treat various types of headaches, lower 
lum bar pain, m y of ascial pain syndr ome, and CRPS with 
B o N T - A  [ 6 , 1 0 - 1 2 ] .  R e c e n t  s t u d i e s  h a v e  s u g g e s t e d  t h a t  
B o N T - A  h a s  a n  e f f e c t  o n  t h e  s e c r e t i o n  o f  n e u r o -
transmitters which are involved in the recognition of pain 
secondary to the analgesic effect due to muscle relaxation 
[6-8].
　　Analgesic mechanisms of BoNT-A can mainly be div-
ided into peripheral, spinal, and cerebrocortical mecha-
nisms. According to Cui et al. [8], the peripheral mecha-
nisms are of interest based on the finding that the sub-
cutaneous  solar  administration  of  BoNT-A  had  a  sig-
nificant analgesic effect in an experimental model of pain 
induced using formalin in rats. In cases of neurogenic in-
flammation, with the initiation of secretions of substances, 
such as substance P, CGRP, and glutamate, local vaso-
dilation, plasma leakage, and the destruction of mast cells 
occ ur. Owing to th ese in fl am m ato ry e v e n ts, br a d y kin in, 
ATP, histamine, and serotonin, which are known to provoke 
hypersensitivity of peripheral nociceptors, accumulate. It 
has been reported that BoNT-A blocks the early stage of 
these  chain  reactions  of  neurogenic  inflammation  and 
thereby  reduces  pain  [8].  Park  et  al.  [13]  clarified  that 
BoNT-A effectively reduced mechanical, cold allodynia in 
a n  a n i m a l  e x p e r i m e n t a l  m o d e l  o f  n e u r o p a t h y .  S u b s e -
quently, according to Ranoux et al. [14], an intradermal in-
jection of BoNT-A had a direct analgesic effect in patients 
wi th l oca l c hr o n i c  n eur o pa th y associ a ted wi th a ll od yn ia. 
These reports provide a theoretical basis for the avail-
ability of BoNT-A for the treatment of neuropathies.
　　The activity of central pain receptors immediately af-
ter pain stimulation can be measured based on the ex-
pression of c-f os, genes associated with the early ex-
pression of pain. BoNT-A blocks the secretion of neuro-
transmitters which are involved in the pathophysiology of 
neurogenic  inflammation,  such  as  glutamate,  secreted 
from the primary afferent pain receptor fibers. BoNT-A 
therefore  reduces  the  extensive  activity  of  dorsal  horn 
neurons  of  the  spinal  cord,  which  has  been  confirmed 
based on the decreased expression of c-fos [6]. BoNT-A 
is involved in the blockage of secretion of the above-men-
tioned  inflammatory  mediators  and  suppresses  the  ex-
pression of c-fos occurring immediately after pain sensa-
t i o n .  I t  c a n  t h e r e f o r e  b e  c o n c l u d e d  t h a t  B o N T - A  s u p-
presses peripheral sensitization, and this leads to central 
desensitization [7].
　　As described herein, in addition to the peripheral and 
spinal cord effects of BoNT-A, the effects on the central 
nervous system have also been examined in many studies. 
With respect to the finding that BoNT-A causes alter-
ations in the sensory pattern via the neural axis, including 
the cerebral cortex, it has been reported that major mech-
anisms altering the overall recognition of pain by BoNT-A 
originate  from  the  neuroplastic  reorganization  of  ex-
citatory and inhibitory balances [15]. Through experimental 
r e su l t s  t h a t  B o N T - A  h a s  a n a n t i - n oc i c e p t i v e  e ff ec t  vi a 
axonal transport to the central nervous system following 
peripheral injection [16], it has been demonstrated that the 
central nervous system is involved in the mechanisms by 
which BoNT-A reduces pain.
　　Alcohol and phenol, which have been commonly used 
for neurolysis, cannot accurately predict drug spread, and 
therefore  these  agents  cannot  block  nerves  selectively. 
Alcohol and phenol cause irreversible destruction. Further-
more,  alcohol  and  phenol  have  been  reported  to  induce 
novel pain [17]. In cases of pain in which radiofrequency 
ablation is used, there exist specialized equipment, such 
as an electrostimulating device and a minute controller. 
Accordingly,  in  these  cases  the  selective  destruction  of 
nerve fibers is possible. There is a lower possibility that 
complications might occur in cases in which neurolysis is 
performed.  The  size  and  location  of  lesions  can  be 
con t r o ll ed. Of th e m eth ods f or b locking ganglion im par, 
radiofrequency ablation is excellent [4]. In cases in which 
ganglion impar is blocked, however, an approach is com-
monly  made  via  the  anococcygeal  ligament.  Because  a 
cannula has a linear form, an accurate approach cannot 
b e  m a d e  t o  t h e  g a n g l i o n  i m p a r .  T h e  p a t i e n t  p r e s e n t e d 
h e r e i n  w a s  a p p r e h e n s i v e  a b o u t  n e u r o l y s i s  u s i n g  r a d i o -
frequency ablation . Accordingly, as an alternative method 
to radiofrequency ablation, blockage of the ganglion impar 
was performed using BoNT-A. Carroll et al. [11] performed 
blockage of lumbar sympathetic ganglia in patients with 
CRPS,  and  compared  treatment  outcomes  between  the 
group in which 0.5% bupivacaine 10 ml was used alone and 
a group in which concomitant use of 75 U BoNT-A and 
0.5% bupivacaine was attempted. As a result, the decrease 
in VAS was markedly greater and the analgesic period was 
prolonged in the group in which bupivacaine 10 ml and 75 
U BoN T-A w as co n c o m itan t l y used f or b l oc k a ge o f th e 
g a n g l i o n  i m p a r .  T h i s  i s  a n  e x a m p l e  d e m o n s t r a t i n g  t h e  
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ical studies rather than animal experiments, which provides 
a basis for the sustained effect and the decrease in V AS 
as compared with cases in which the patient underwent 
blockage of the ganglion impar using conventional types 
of local anesthetics. Accordingly, as shown in animal ex-
periments in which formalin was used [8], the mechanism 
of BoNT-A is not referred to as direct destruction of nerve 
fibers,  rather  based  on  blockage  of  pain-controlling 
neurotransmitters. A reversible, transient analgesic effect 
is considered one of the advantages in the current case, 
and. in agreement with an experimental animal reports by 
Kim et al. [18] in which BoNT-A caused no marked histo-
p a t h o l o g i c  c h a n g e s  a s  c o m p a r e d  w i t h  c a s e s  i n  w h i c h  
blockage was done using alcohol or phenol, and the effects 
were persistently present for ＞ 1 month.
　　In the current case, the use of BoNT-A for blockage 
of the ganglion impar was safer than neurolysis based on 
the previous types of chemical or high-frequency ablation. 
The effects were superior to cases in which local anes-
thetics  were  solely  used,  and  the  analgesic  period  was 
prolonged. Based on these advantages, BoNT-A is pro-
posed as a new method for blocking the sympathetic nerv-
ous system. Aside from these advantages, there are also 
disadvantageous in that BoNT-A can pose a safety issue. 
BoNT-A is rather expensive and requires serial use. In as-
sociation with this, in adults weighing 70 kg in which the 
LD50 of BoNT-A amounts to 3,000 U, the common clinical 
dose is at most 25-100 U and it can therefore be consid-
ered very safe. BoNT-A is used at 3-6 month intervals, 
and the proportion of antibody formation has been re-
ported to be ＜ 4% [5,19]. The problem that the drug effect 
is lost due to the formation of antibodies following repeated 
use can also be resolved [5,19]. It it has been reported that 
the use of BoNT-A reduces the amount of analgesic drugs, 
the need for treatment, and the length of hospital stay as-
sociated  with  the  side  effects  of  drugs  [20].  Together, 
these  features  may  overcome  the  cost  associated  with 
BoNT-A. Because the number of cases in which BoNT-A 
has been used for the blockage of ganglion impar is lim-
ited, further clinical studies and application are needed.
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